Boston, Feb. 25, 2026 (GLOBE NEWSWIRE) -- According to the latest BCC Research report, “Global Markets and Technologies for Advanced Drug Delivery Systems - Focus on Routes of Administration” is projected to grow from $299.6 billion in 2025 to $487.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.2% from 2025 to 2030.
The report on Advanced Drug Delivery Systems (ADDS) provides a comprehensive analysis of the global market, including current trends, forecasts, and competitive dynamics. It highlights the drivers, restraints, and opportunities influencing industry growth. The study emphasizes segmentation by route of administration, technology, carrier, and therapeutic application, covering areas such as enteral, parenteral, nasal, transdermal and implant-based delivery systems.
Additionally, the report explores regional market performance across North America, Europe, Asia-Pacific, MEA, and South America, with detailed country-level insights. It evaluates the impact of regulatory frameworks, technological advances, and emerging trends on market development. By assessing market shares of leading manufacturers and projecting long-term growth, the report offers strategic guidance for stakeholders to capitalize on innovations in targeted, extended, and pulsatile-release drug delivery technologies.
The factors driving the market include:
Increasing Incidence of Chronic Diseases: The growing prevalence of chronic illnesses like diabetes, cancer, and cardiovascular disorders drives demand for advanced drug delivery systems that ensure sustained release, better compliance, and improved therapeutic outcomes.
Nanotechnology in Advancing Drug Delivery: Nanotechnology enables precise targeting and controlled drug release. Nanocarriers improve solubility, and bioavailability, and can cross biological barriers, making treatments more effective and reducing side effects.
Advances in Therapeutics and Material Science: Innovations in biologics, peptides, and gene therapies require new delivery methods. Advanced materials like biodegradable polymers and smart hydrogels allow controlled release and enhance safety and compatibility.
R&D Spending by Manufacturers: Pharmaceutical companies are investing in research to develop novel drug delivery platforms and routes of administration, accelerating innovation and regulatory approvals for advanced systems.
Rise in Government Funding: Government initiatives and public-private partnerships provide financial support for healthcare innovation, encouraging cost-effective and patient-friendly drug delivery technologies.
Request a sample copy of the global market for advanced drug delivery systems report.
Report Synopsis
| Report Metric | Details |
| Base year considered | 2024 |
| Forecast period considered | 2025-2030 |
| Base year market size | $275.2 billion |
| Market size forecast | $487.4 billion |
| Growth rate | CAGR of 10.2% from 2025 to 2030 |
| Segments covered | Route of Administration (RoA), Technology, Application, Drug Vehicle/Carrier, and Region |
| Regions covered | North America, Europe, Asia-Pacific, the Middle East and Africa (MEA) and South America |
| Countries covered | U.S., Canada, Mexico, Brazil, Argentina, Germany, U.K., France, Italy, Spain, Japan, China, South Korea, Australia, India, The Middle East and Africa |
| Market drivers |
|
Innovations
- In 2023, Gilead Sciences signed a strategic development and funding agreement with Abingworth LLP, a life sciences investment group, for up to $210 million to fund specific clinical studies for Gilead’s drug, Trodelvy, in the treatment of non-small cell lung cancer (NSCLC) from 2023 to 2026. The agreement includes a success-based payment structure, with Abingworth entitled to a fixed milestone payment of up to $84 million and royalties based on the drug’s net sales.
- In 2024, AbbVie acquired ImmunoGen, a leading antibody-drug conjugate (ADC) company, to broaden its oncology portfolio, including ELAHERE, a key asset used to treat folate receptor-alpha-positive platinum-resistant ovarian cancer.
- In 2025, AbbVie and Xilio Therapeutics formed a strategic alliance to advance oncology treatments. The partnership focuses on developing next-generation antibody-based immunotherapies, known as “masked” T-cell engagers, which remain inactive until they reach the tumor’s microenvironment. This targeted approach leverages AbbVie’s cancer research expertise and Xilio’s unique technology to create more effective and precise cancer treatments.
Emerging startups
- Aclaris Therapeutics Inc.
- Acrotech Biopharma Inc.
- Adaptimmune
AI Impact on the Market for Advanced Drug Delivery Systems
AI is revolutionizing the drug delivery system market by optimizing the entire development pipeline, from formulation design to clinical trial optimization. This reduces R&D time and costs, paving the way for personalized medicine. The AI-powered drug delivery market is experiencing rapid growth, with significant spending on AI technologies projected to increase.
For an in-depth analysis of AI’s impact on this sector, explore the complete AI Impact on Advanced Drug Delivery Systems - BCC Pulse Report
The report addresses the following questions:
- What are the projected market size and growth rate?
- The market for advanced drug delivery systems is projected to reach $487.4 billion by the end of 2030, with a CAGR of 10.2%.
- What factors are driving the growth of the market?
- Key drivers include:
- Increasing incidence of chronic diseases.
- Nanotechnology in advancing drug delivery.
- Advances in therapeutics and material science.
- Increased R&D spending by market players.
- Rise in government funding.
- What are the challenges and opportunities of the market?
- Key challenges include:
- Route-specific barriers.
- Limitations with nanotechnology and nanoparticles.
- Challenges with nanoformulations in ADDS.
- Key opportunities include:
- Cost-efficiency of advanced drug delivery systems.
- Mechanism of nanoparticles in overcoming drug resistance.
- Emerging markets.
- Which market segments are covered in the report?
- The market is segmented by route of administration, technology, vehicle/carrier, application, and region.
- Which route of administration will be dominant through 2030?
- The enteral route of administration will continue to dominate the market through the end of 2030. The transdermal route will also show strong growth of the enteral routes is, oral RoA is preferred due to its high patient acceptance, non-invasiveness, and logistical and economic benefits throughout the drug development and commercialization lifecycle. Transdermal patches are a non-invasive, painless and self-administrable alternative to traditional injections, making them ideal for global vaccination campaigns and chronic disease management.
- Which region has the largest market share?
- North America will continue to dominate the market through the end of 2030. The Asia-Pacific region shows the highest CAGR. The North American market is driven by the R&D pipelines of key industry players. The Asia-Pacific market is fueled by government approvals and clinical trials, with China and India leading the way.
Market leaders include:
- ABBOTT
- ABBVIE INC.
- AMGEN INC.
- ASTRAZENECA
- BAXTER
- BAYER AG
- BOSTON SCIENTIFIC CORP.
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- GSK PLC
- JAZZ PHARMACEUTICALS INC.
- JOHNSON & JOHNSON
- MERCK & CO. INC.
- NOVARTIS AG
- PFIZER INC.
- SANOFI
Related reports:
Global Markets for Allergy Diagnostics and Treatments: This report provides a comprehensive analysis of the allergy diagnostics and treatment market, covering key segments such as diagnostics (skin and blood tests) and treatments (antihistamines, corticosteroids, immunotherapy, and others). Immunotherapy is further divided into subcutaneous and sublingual methods, while treatments are categorized by allergen type and drug type (prescription and OTC). The report examines market trends, drivers, restraints, opportunities, and the competitive landscape across major regions, including North America, Europe, Asia-Pacific, MEA, and South America, highlighting current and future market potential.
Cancer Immunotherapy: Technologies and Global Markets: This report provides a detailed analysis of the cancer immunotherapy market, focusing on its current and future potential, competitive landscape, and as the market’s drivers, restraints, and opportunities. It segments the market by therapy type (including checkpoint inhibitors, monoclonal antibodies, adoptive cell therapies, cancer vaccines, and others), cancer type (such as melanoma, leukemia, lymphoma, lung, breast, and colorectal cancers), and region (North America, Europe, Asia-Pacific and Rest of the World). The report also examines market size, forecasts, growth trends and shares of major players, offering insights into industry structure and long-term impacts on the global cancer immunotherapy market.
Purchase a copy of the report directly from BCC Research.
For further information or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
